Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 690517 monotherapy and in combination with empagliflozin in chronic kidney disease
CTR20220515Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vicadrostat in chronic kidney disease (CKD), sponsored by Boehringer Ingelheim. Started Mar 2022; status: completed.
02
Drugs
vicadrostat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20220515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220515.